KR20060083800A - Ink for correction of vitiligo and low pigmentation using dopamelanin pigment - Google Patents
Ink for correction of vitiligo and low pigmentation using dopamelanin pigment Download PDFInfo
- Publication number
- KR20060083800A KR20060083800A KR1020050004742A KR20050004742A KR20060083800A KR 20060083800 A KR20060083800 A KR 20060083800A KR 1020050004742 A KR1020050004742 A KR 1020050004742A KR 20050004742 A KR20050004742 A KR 20050004742A KR 20060083800 A KR20060083800 A KR 20060083800A
- Authority
- KR
- South Korea
- Prior art keywords
- melanin
- vitiligo
- dopamelanin
- pigments
- dopa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 8
- 239000000049 pigment Substances 0.000 title abstract description 14
- 208000012641 Pigmentation disease Diseases 0.000 title abstract 2
- 230000019612 pigmentation Effects 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 claims abstract 3
- 239000002994 raw material Substances 0.000 claims 1
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 18
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract description 5
- 239000000084 colloidal system Substances 0.000 abstract description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 2
- 102000003425 Tyrosinase Human genes 0.000 abstract description 2
- 108060008724 Tyrosinase Proteins 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000037311 normal skin Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
멜라닌색소는 동물이나 식물에 흔히 존재하며 이들의 생합성은 타이로시나제 라는 효소의 작용으로 아미노산인 타이로신이 도파로 만들어지고 도파는 도파퀴논으로 변하면서 이들이 서로 중합하여 만들어진다. 그러나 엘도파라는 물질은 여러가지 pH 농도에서 공기중의 산소와 반응하여 스스로 산화되어 도파퀴논으로 되면서 중합하여 생체 내에서 만들어지는 멜라닌 색소와 유사한 중합화합물이 되고 이들은 액상의 콜로이드 형태로 존재하게 된다. 이러한 콜로이드의 농도는 pH를 조정하여 다양하게 멜라닌량을 조절할수 있고 또한 고농도로 만들어진 것은 적당량 희석하여 색상을 조절할 수 있다. 이에 본 발명자는 이들 도파 멜라닌 콜로이드액을 이용하여 피부에 착색을 유도 할 수 있다고 생각되어 백반증 및 저색소반에서의 도파멜라닌을 피부에 주입하여 치료에 이용하는 것에 관하여 특허출원 심사를 받고자한다. Melanin pigments are commonly present in animals and plants, and their biosynthesis is caused by the action of an enzyme called tyrosinase to make amino acids tyrosine into dopas and dopas into dopaquinones, which are polymerized together. However, eldopara is reacted with oxygen in the air at various pH concentrations to oxidize itself into dopaquinone and polymerize to form melanin pigments that are produced in vivo, and they exist in the form of liquid colloids. The concentration of these colloids can be adjusted in various ways to adjust the melanin amount, and also made of high concentration can be adjusted by diluting the appropriate amount. Accordingly, the present inventors believe that the dopa melanin colloidal fluid can be used to induce pigmentation on the skin. Thus, the present inventors intend to undergo a patent application examination regarding the use of dopa melanin in vitiligo and low pigmented plaques for skin treatment.
도파멜라닌, 백반증, 저색소성병소 Dopamelanin, vitiligo, hypopigmentary lesion
Description
본 도파 멜라닌색소는 의료용 및 화장품류의 기술 분야로 분류 할수 있고 이와 가장 유사한 종래의 기술은 문신과 같다. 현재 문신에 사용되는 잉크는 탄소, 타이다니움 옥사이드, 아이언 옥사드등이 사용되고 있으나 이들은 피부에 있는 멜라닌 색소가 아닌 관계로 주위 피부색과 조화를 이루기에 매우 어려운 점이 있으며 이들 색소가 주위 피부로 번지는 경우가 흔하여 백반증이나 저색소증에서 사용하기에는 문제가 있어 왔다. 이에 본 발명자는 피부색과 가장 유사하며 피부에 이식후에도 정상 피부와 가장 유사한 도파멜라닌을 발명하였다.The dopa melanin pigment can be classified into the technical field of medical and cosmetics, and the most similar conventional technology is like a tattoo. Currently, the ink used for tattoos is carbon, Titanium oxide, iron oxad, etc., but these are not melanin pigments on the skin, so it is very difficult to harmonize with the surrounding skin color. Often, there have been problems with use in vitiligo or hypopigmentation. Thus, the inventors invented dopamelanin, which is most similar to skin color and most similar to normal skin even after transplantation into the skin.
피부색은 주로 피부중 표피에 있는 멜라닌 색소에 따라 크게 흑인, 황인, 백인으로 나눌수 있다. 멜라닌 색소의 생합성은 타이로신으로부터 타이로시나제의 효소에 의해 만들어지나 엘도파(L-DOPA, L-dioxyphenylalanine)로부터 자연적인 산화 로 이루어 지기도한다. 이에 본 발명자는 엘도파를 여러가지 알카리 용액에 노출 시키면 다양한 농도의 도파멜라닌 색소를 만들수 있다는 사실과 이들 색소를 피부에 주입하면 자연적인 피부 색조를 얻을 수 있음을 발견하였다. 이들 색소를 백반증 및 저색소성 반에 주입하면 주위의 정상적인 피부색과 유사한 색조의 회복을 가져올 수 있음을 확인하였다. 도파멜라닌 색소를 만드는 방법은 엘도파를 수산화나트륨 0.001 M 에서 0.04M 의 여러가지 농도의 용액에 녹이고 이들을 밀폐용기에 넣은 후 산소와 약 5일간 노출시키면, 이들은 수산화 나트륨의 농도에 따라 다양한 농도의 포화 도파멜라닌 콜로이드가 용액중에 생성되고 이들 액의 알카리 pH는 산화과정을 거치면서 마지막으로는 중성 pH를 나타낸다는 것을 발견하였다. 그리고 불포화 엘도파는 2000 rpm에서 원심 분리하면 침전물로서 분리된다. 이중 상층액을 취하여 백반증의 환부 혹은 저색소반의 피부중 상부 진피에 주입하면 정상과 유사한 피부색을 회복 시킬 수 있다.
Skin color can be largely divided into black, yellow, and white depending on the melanin pigment in the epidermis of the skin. The biosynthesis of melanin pigments is made by tyrosine from tyrosinase enzymes, but also by natural oxidation from L-DOPA (L-dioxyphenylalanine). Accordingly, the present inventors have found that when the EL dopa is exposed to various alkaline solutions, dopamelanin pigments of various concentrations can be made, and natural pigments can be obtained by injecting these pigments into the skin. Injecting these pigments into vitiligo and hypopigmented plaques has been shown to lead to recovery of the tone similar to the normal skin color of the surroundings. The method of making dopamelanin pigment is to dissolve eldopa in a solution of various concentrations from 0.001 M to 0.04 M sodium hydroxide, put them in an airtight container and expose them to oxygen for about 5 days, and they are saturated in various concentrations depending on the concentration of sodium hydroxide. It was found that melanin colloids were formed in the solution and the alkali pH of these solutions finally showed neutral pH as they were oxidized. And unsaturated eldopa is separated as a precipitate by centrifugation at 2000 rpm. Taking the supernatant and injecting it into the upper dermis of the affected or visceral plaque of the vitiligo can restore normal skin color.
엘도파멜라닌색소 및 여러가지 농도(농담)의 색소 Eldo pamelanin pigments and pigments of various concentrations (light)
백반증 및 저색소성 반점의 정상 피부색을 회복함으로서 개인의 행복추구 및 이들의 제조에 따른 제약업 및 화장품산업의 발전을 기대할 수 있다.By restoring the normal skin color of vitiligo and hypopigmented spots, it is possible to expect the development of the pharmaceutical industry and the cosmetic industry according to the pursuit of happiness of individuals and their manufacture.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050004742A KR20060083800A (en) | 2005-01-18 | 2005-01-18 | Ink for correction of vitiligo and low pigmentation using dopamelanin pigment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050004742A KR20060083800A (en) | 2005-01-18 | 2005-01-18 | Ink for correction of vitiligo and low pigmentation using dopamelanin pigment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060083800A true KR20060083800A (en) | 2006-07-21 |
Family
ID=37174089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050004742A Ceased KR20060083800A (en) | 2005-01-18 | 2005-01-18 | Ink for correction of vitiligo and low pigmentation using dopamelanin pigment |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20060083800A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016170424A1 (en) * | 2015-04-22 | 2016-10-27 | Body Smart Ltd. | Methods apparatus and compositions for changeable tattoos |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508706A (en) * | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| US4806360A (en) * | 1987-10-23 | 1989-02-21 | Advanced Polymer Systems | Synthetic melanin aggregates |
| US5100654A (en) * | 1989-04-07 | 1992-03-31 | Yale University | Phosphorylated derivatives of l-dopa and compositions and methods for increasing the melanin content in mammalian skin and hair |
| KR19990004224A (en) * | 1997-06-27 | 1999-01-15 | 서경배 | Cosmetic composition inducing pigmentation reaction in the formulation |
-
2005
- 2005-01-18 KR KR1020050004742A patent/KR20060083800A/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508706A (en) * | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| US4806360A (en) * | 1987-10-23 | 1989-02-21 | Advanced Polymer Systems | Synthetic melanin aggregates |
| US5100654A (en) * | 1989-04-07 | 1992-03-31 | Yale University | Phosphorylated derivatives of l-dopa and compositions and methods for increasing the melanin content in mammalian skin and hair |
| KR19990004224A (en) * | 1997-06-27 | 1999-01-15 | 서경배 | Cosmetic composition inducing pigmentation reaction in the formulation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016170424A1 (en) * | 2015-04-22 | 2016-10-27 | Body Smart Ltd. | Methods apparatus and compositions for changeable tattoos |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105362088B (en) | Polypeptide composition for whitening, brightening and lightening spots | |
| MX2009000693A (en) | Use of a rice protein hydrolysate as pigmenting active principle. | |
| JP6843946B2 (en) | Enzyme-based cosmetic composition | |
| US20210259947A1 (en) | Method for obtaining an aqueous extract of dunaliella salina and cosmetic uses of same | |
| ES2355818T7 (en) | Use of lignin peroxidase in skin and hair clearance | |
| Mago et al. | Mushroom based cosmeceuticals: An upcoming biotechnology sector | |
| EP3504218B1 (en) | Composition comprising silicon and method for preparing same | |
| KR20060083800A (en) | Ink for correction of vitiligo and low pigmentation using dopamelanin pigment | |
| TW201700108A (en) | Phalaenopsis extract for whitening skin and resisting skin aging capable of reducing the activity of tyrosinase and being anti-oxidative , capable of whitening the skin and slowing down the phenomenon of skin aging | |
| KR20110094453A (en) | Cosmetic Compositions Containing Antioxidant Foods and Edibles Using Yeast Mold | |
| KR102486936B1 (en) | Cosmetics compositions for skin whitening | |
| KR20110091342A (en) | Whitening cosmetic composition using yeast mold | |
| KR102011654B1 (en) | Cosmetic composition comprising oysters, sea cucumber, sea squirt, Aplysia kurodai and buccinum striatissimum | |
| KR20200077649A (en) | Cosmetic composition comprising the extract from BSF larva and method of preparing the same | |
| CN108524352A (en) | A kind of radioresistance preparation and its application | |
| Moh et al. | Characteristics and applications of bioactive peptides in skin care | |
| KR101126136B1 (en) | Cosmetic Composition for Skin-whitening and Antibacterial Activity | |
| FR3062302A1 (en) | NOVEL COSMETIC COMPOSITION COMPRISING NACRE OR A NACRE EXTRACT | |
| JP2009256225A (en) | Cosmetic | |
| KR20170036276A (en) | Cosmetics compositions for skin whitening | |
| Pandey et al. | Melanin: progress, prospects, and challenges in synthesis and commercial applications | |
| TW201700109A (en) | Phalaenopsis extract and use thereof with activity of reducing tyrosinase and resisting oxidation for whitening the skin and slowing down the skin aging phenomenon | |
| JPH10194960A (en) | Skin cosmetic | |
| CN108434076A (en) | A kind of skin repair essence microcapsules and preparation method thereof | |
| TWI645861B (en) | Extract of ganoderma formosanum mycelium for skin lightening and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20050118 |
|
| PA0201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20050618 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060629 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20060915 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060629 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |